Pharmafile Logo
Pharmafocus logo
Advanced Search

J&J

Showing 15 posts of 227 posts found.

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 29, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma

Summer seems to be in full swing as we reach the end of June, so it’s time to look back …

News
sandi_peterson

J&J’s second-in-command to retire, alongside executive restructure

June 25, 2018
Medical Communications, Sales and Marketing J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson’s Group Worldwide Chairman Sandra Peterson (pictured) has announced she is to retire from her role and the …

News
janssen_latest_logo_on_sign_closer

Janssen debuts promising new cancer data at ASCO

June 4, 2018
Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma

Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, AstraZeneca, Cancer, Gilead, HIV, J&J, JJ, google, machine learning, melanoma, pharma, top ten

The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …

News
jj

J&J terminates PD-(L)1 combo studies of cancer therapy Darzalex

May 29, 2018
Manufacturing and Production, Research and Development Cancer, Genmab, J&J, JJ, Johnson & Johnson, Roche, darzalex, multiple myeloma, tecentriq

Johnson & Johnson is to terminate its studies investigating Genmab’s CD38-targeting, human IgG1κ monoclonal antibody Darzalex (daratumumab) in combination with …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical

It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …

News
jj

J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

News
kris-sterkens-23052017-hr-1

Working Life: Kris Sterkens, Company Group Chairman, Janssen EMEA

April 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, Kris Sterkens, pharma

Pharmafile.com sat down with Kris Sterkens, Company Group Chairman of Janssen’s EMEA operations to discuss nearly three decades at the …

Feature
shutterstock_274590824

J&J pays out $37m in damages over claims its talc contains asbestos

April 6, 2018
Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, mesothelioma, ovarian cancer, pharma, talc

Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …

News
dominic_caruso

J&J’s longest-standing CFO finally steps down

March 21, 2018
Medical Communications, Research and Development J&J, JJ, Johnson & Johnson, biotech, cfo, drugs, pharma, pharmaceutical

Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from …

News
jj

J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup

February 15, 2018
Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer

Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, Antibiotics, Avycaz, Elastagen, FDA, GSK, India, J&J, JJ, Nektar Therapeutics, Novartis, Theravance, artificial intelligence, pharma

It’s top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research …

News

FDA expands J&J Zytiga combo’s indication to include castration-sensitive prostate cancer

February 9, 2018
Medical Communications, Sales and Marketing Cancer, FDA, J&J, JJ, Janssen, Johnson & Johnson, Zytiga, pharma

Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the …

News

J&J’s apalutamide shows strength in non-metastatic prostate cancer

February 7, 2018
Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer

Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026